Engineered immune cells take on Hard-to-Treat pancreatic cancer
NCT ID NCT04146298
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a personalized cell therapy for advanced pancreatic cancer. Patients receive their own immune cells that have been engineered to recognize and attack cancer cells with a specific mutation (KRAS G12V). The study enrolls 30 people whose tumors carry this mutation and a specific immune type (HLA-A*11:01). The goal is to see if the treatment is safe and can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mutant KRAS G12V-specific TCR transduced autologous T cells
What this could lead to
If it works, this could point toward a new treatment option for advanced pancreatic cancer patients with the KRAS G12V mutation.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to everyone. There are risks of serious side effects from the chemotherapy and cell infusion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital
RECRUITINGShanghai, 200433, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••